Last reviewed 2026-05-14 · How we verify

Follitropin beta injection 300 IU

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Injection site pain
• Abortion spontaneous
• Headache
• Vomiting in pregnancy
• Haemorrhage in pregnancy
• Morning Sickness
• Abortion missed
• Upper respiratory tract infection
• Hydrometra
• Biochemical Pregnancy
• Abortion Spontaneous
• Pelvic discomfort

Key clinical trials

• A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China (PHASE3)
• A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation (PHASE3)
• Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells (PHASE1)
• To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (PHASE3)
• Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031) (PHASE3)
• Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve (NA)
• Type of Gonadotropin and Embryo Kinetics of Development (PHASE4)
• An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Follitropin beta injection 300 IU CI brief — competitive landscape report
• Follitropin beta injection 300 IU updates RSS · CI watch RSS
• ART Fertility Clinics LLC portfolio CI